Innate Pharma S.A. IPHA
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -50.66%
- 1 year
- -52.56%
5D -0.5020 (-35.10%)
- Market cap
- 96.44M
- Revenue (ttm)
- 33.79M
- Profit margin
- -100.78%
- EPS (ttm)
- -0.59
- Shares out
- 82.78M
- Forward P/E
- 4.67
- YTD return
- -50.66%
- 1-year return
- -52.56%
- 50-day average
- 1.82
- Volume
- 18.03K
- Avg volume
- 43.17K
- Open
- 0.8841
- Previous close
- 0.9399
- Day's range
- 0.829 – 0.9084
- 52-week range
- 0.829 – 2.71
- Beta
- 0.87
- Analysts
- Buy
- Price target
- 7.41 (+758.5%)
Key statistics
- 200-day average
- 2.23
- Enterprise value
- 109.65M
- Price / sales
- 5.25
- Price / book
- 5.90
- Revenue growth
- -69.30%
- Free cash flow
- 13.06M
- Total cash
- 91.80M
- Total debt
- 35.50M
- Return on equity
- -78.59%
- Short % of float
- 0.14%
Fundamental scorecard
1 of 25 checks passed on IPHA’s reported financials
1of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 0 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Mar 23, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Mar 24, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Mar 18, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- innate-pharma.com
News
Innate Pharma S.A. (IPHA) Discusses IPH4502 Phase 1 Clinical Data and Development Outlook Transcript
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026 Innate Pharma 9M Revenue €3.4M Vs €2.3M YoY, Cash €96.8M; CFO Frédéric Lombard To Step Down December 31
Your note
Sign in to keep a note on IPHA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Optiver Holding B.v. | 0.10% | 86,788 | 182.25K | Sep 29, 2024 |
| Exchange Traded Concepts LLC | 0.09% | 77,350 | 162.43K | Sep 29, 2024 |
| Morgan Stanley | 0.05% | 43,524 | 91.40K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.03% | 21,267 | 44.66K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 8,408 | 17.66K | Sep 29, 2024 |
| Rhumbline Advisers | 0.00% | 205 | 430 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ETF Series Solutions-Range Cancer Therapeutics ETF | 0.09% | 73,688 | 154.74K | Aug 30, 2024 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.08% | 64,826 | 136.13K | Aug 30, 2024 |
